Source comparison
Sermorelin Growth Hormone Release Research: Peptide Comparison
Sermorelin GHRH receptor agonist (cAMP-PKA pathway) 15–30 minutes post-injection 90–120 minutes Circadian GH dynamics, HPA axis studies, pituitary reserve assessment MK-677 Ghrelin receptor agonist (oral bioavailability) 60–90 minutes post-dose 24+ hours (long
This comparison does not assign a generated winner or score.
- Sermorelin
- GHRH receptor agonist (cAMP-PKA pathway)
- 15–30 minutes post-injection
- 90–120 minutes
- Circadian GH dynamics, HPA axis studies, pituitary reserve assessment
- MK-677
- Ghrelin receptor agonist (oral bioavailability)
- 60–90 minutes post-dose
- 24+ hours (long half-life)
- Chronic GH elevation models, anabolic signaling research, cachexia studies
- GHRP-2
- Ghrelin receptor agonist (injectable)
- 20–40 minutes post-injection
- 2–3 hours
- Acute GH pulse studies, stress response models, appetite signaling research
- CJC-1295
- GHRH analog with extended half-life
- 1–4 hours post-injection
- 6–8 days (DAC variant)
- Long-term anabolic research, IGF-1 upregulation studies, reduced dosing frequency
- Hexarelin
- GHSR-1a agonist (high receptor affinity)
- 15–25 minutes post-injection
- 2–4 hours
- Maximal GH secretory capacity testing, cardiac peptide research